版本:
中国

BRIEF-Glenmark Pharmaceuticals reports positive results from phase 3 trial of gsp 301

March 29 Glenmark Pharmaceuticals Ltd

* Glenmark Pharmaceuticals reports positive results from a Phase 3 trial of GSP 301, Mometasone/Olopatadine fixed-dose combination nasal spray, in seasonal allergic rhinitis

* In trial treatment with GSP 301 demonstrated statistically significant and clinically meaningful improvement from baseline

* All investigational treatments administered in trial were well-tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐